LOS ANGELES, CA — December 9, 2025 — Leads & Copy — Immix Biopharma, Inc. (Nasdaq: IMMX) has announced the closing of its previously announced underwritten registered offering, which included 19,117,646 shares of its common stock priced at $5.10 per share.
The company also offered, in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price of $5.09 per pre-funded warrant. This price represents the per-share public offering price for the common stock, less the $0.01 per share exercise price for each pre-funded warrant.
After deducting underwriting discounts, commissions, and other offering expenses, Immix is expected to receive net proceeds of approximately $93.7 million from the offering.
According to Immix, the financing includes leading U.S. biotechnology institutional investors and mutual funds.
Morgan Stanley served as the sole book-running manager for the offering, while Citizens Capital Markets and Mizuho acted as co-managers.
The securities in the registered offering were offered and sold under a “shelf” registration statement on Form S-3 (File No. 333-269100), including a base prospectus, filed with the U.S. Securities and Exchange Commission (SEC) on January 3, 2023, and declared effective on January 11, 2023. A prospectus supplement and accompanying prospectus detailing the terms of the registered offering has been filed with the SEC and is accessible on its website.
Copies of the prospectus supplement and accompanying prospectus related to the offering can be obtained from Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at 1-866-718-1649, or by email at prospectus@morganstanley.com.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is focused on relapsed/refractory AL Amyloidosis. Its lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” designed to filter out non-specific activation. NXC-201 is currently being evaluated in the U.S. multi-center study NEXICART-2 (NCT06097832) for relapsed/refractory AL Amyloidosis, with a registrational design. NXC-201 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US FDA and Orphan Drug Designation (ODD) by the FDA and in the EU by the EMA.
Mike Moyer of LifeSci Advisors can be reached at mmoyer@lifesciadvisors.com.
Gabriel Morris, CFO, can be reached via irteam@immixbio.com.
Source: Immix Biopharma, Inc.
